{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ibrance&page=7", "query": { "intervention": "Ibrance", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 230, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ibrance&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ibrance&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T18:51:49.854Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06495164", "title": "A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Malignant Neoplasm of Breast" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Aromatase inhibitor", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-06-24", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06495164" }, { "nct_id": "NCT00721409", "title": "Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PD 0332991", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 177, "start_date": "2008-09-15", "completion_date": "2017-12-20", "has_results": true, "last_update_posted_date": "2019-11-04", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 51, "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 24 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00721409" }, { "nct_id": "NCT03147287", "title": "Palbociclib After CDK and Endocrine Therapy (PACE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2017-09-05", "completion_date": "2026-12-30", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 22, "location_summary": "Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 18 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03147287" }, { "nct_id": "NCT01740427", "title": "A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "PD-0332991", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 666, "start_date": "2013-02-22", "completion_date": "2023-11-09", "has_results": true, "last_update_posted_date": "2024-11-14", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 136, "location_summary": "Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more", "locations": [ { "city": "Bellflower", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01740427" }, { "nct_id": "NCT02264613", "title": "ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Lymphoma", "Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "ALRN-6924", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aileron Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2014-10", "completion_date": "2020-04", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Duarte, California • Denver, Colorado + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02264613" }, { "nct_id": "NCT02101034", "title": "PD 0332991 and Cetuximab in Patients With Incurable SCCHN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell of Head and Neck" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "PD 0332991", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2014-06-17", "completion_date": "2023-11-10", "has_results": true, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Westwood, Kansas • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101034" }, { "nct_id": "NCT03959891", "title": "AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 77, "start_date": "2019-05-30", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03959891" }, { "nct_id": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Anatomic Stage IV Breast Cancer AJCC v8", "Anemia", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Castration-Resistant Prostate Carcinoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid System Neoplasm", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Primary Myelofibrosis", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Myeloproliferative Neoplasm", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Myelodysplastic Syndrome", "Refractory Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Primary Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dacomitinib", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Tretinoin", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 2, "start_date": "2020-04-01", "completion_date": "2020-12-10", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878524" }, { "nct_id": "NCT02738866", "title": "Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2016-10-25", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 5, "location_summary": "Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 2 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Annapolis", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "West Reading", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02738866" }, { "nct_id": "NCT04436744", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Giredestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 221, "start_date": "2020-09-04", "completion_date": "2021-11-24", "has_results": true, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-10-24T18:51:49.854Z", "location_count": 10, "location_summary": "Burbank, California • Laguna Hills, California • San Luis Obispo, California + 7 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04436744" } ] }